HEALTH CARE DECISIONS USING OUTCOMES RESEARCH CASE STUDIES
CASE1 |
UTILIZING AN INTERNET-BASED SYSTEM TO DELIVER A PHARMACY-CENTRIC ALERT AND INTERVENTION IN A MANAGED CARE SETTING |
|
Fazio J, Orr G, Singal R |
|
WorldDoc, Las Vegas, NV, USA |
| |
|
CASE2 |
ISSUES WHEN COMPARING COSTS AND EFFECTS OF INHALED ASTHMA AND COPD MEDICATIONS |
|
Engstrom A1, Hugosson K2 |
|
1LFN Pharmaceutical Benefits Board, Solna, Sweden; 2 Pharmaceutical Benefits Board, Solna, Sweden |
| |
|
CASE3 |
REVIEWING THE REIMBURSEMENT STATUS OF DRUGS AGAINST ASTHMA, COPD AND COUGHS |
|
Hugosson H1, Engstrom A2 |
|
1Pharmaceutical Benefits Board, Solna, Sweden; 2 LFN Pharmaceutical Benefits Board, Solna, Sweden |
| |
|
CASE4 |
DEVELOPMENT AND VALIDATION OF A CAREGIVER GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE |
|
Deiratany S |
|
The Hospital for Sick Children, Toronto, ON, Canada |
|
|
CANCER
PCN1 |
QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA |
|
Simons WR1, Aamdal S2, Hauschild A3, Mohr P4, Grob JJ5 |
|
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Cancer Clinic, Oslo, Norway, 3Universitats-Hautklinik, Kiel, Germany, 4Dermatologisches Zentrum, Buxtehude, Germany, 5Chu Hospitalier Sainte-Marguerite, Marseille, France |
| |
|
PCN2 |
RETROSPECTIVE CHART REVIEW OF THE MANAGEMENT OF HAND-FOOT SYNDROME IN THE TREATMENT OF COLORECTAL CANCER |
|
Ralston SJ1, Almond J1, Holtz D2 |
|
1Merck Serono, Feltham, Middlesex, UK, 2Merck Serono, West Drayton, Middlesex, UK |
| |
|
PCN3 |
ECONOMIC IMPACT OF SECOND- AND THIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER: A FRENCH OBSERVATIONAL STUDY. |
|
Chouaid C1, Vergnenegre A2, Moser A3, Coudray-Omnes C3 |
|
1CHU Saint Antoine, APHP, Paris, France, 2CHU Limoges, Limoges, France, 3Roche Pharma, Neuilly sur Seine cedex, France |
| |
|
PCN4 |
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING HEXAMINOLEVULINATE (HEXVIX) CYSTOSCOPY COMPARED TO WHITE LIGHT CYSTOSCOPY IN BLADDER CANCER PATIENTS |
|
Colombo GL1, Di Matteo S1, Vinci M1, Caruggi M2 |
|
1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy, 2Università degli Studi dell'Insubria, Varese, Italy |
| |
|
PCN5 |
THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL |
|
Souza FH, Viana LS, Nunes JS, Schroeter D, Serrano SV |
|
Hospital de Cancer de Barretos, Barretos, SP, Brazil |
| |
|
PCN6 |
HOSPITALIZATION COSTS FOR TWO METHODS OF TSH STIMULATION DURING THE RADIOIODINE ABLATION IN THYROID CANCER PATIENTS |
|
Borget I1, Schlumberger M1, Ricard M2, Remy H2, Allyn M3, De Pouvourville G4 |
|
1Gustave Roussy Institute, Villejuif, France, 2Institut de cancérologie Gustave Roussy, Villejuif, France, 3genzyme corporation, Cambridge, MA, USA, 4ESSEC Business School, Cergy-pontoise, France |
| |
|
PCN7 |
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN |
|
Lopez A1, Arocho R2, Atchison C3, Malin JL4, Liu Z5, Doan QV5, Dubois RW5 |
|
1Vall d’Hebron University Hospital, Barcelona, Spain, 2Amgen SA, Barcelona, Spain, 3Amgen (Europe) Gmbh, Zug, Switzerland, 4Amgen Inc, Thousand Oaks, CA, USA, 5Cerner Corporation, Beverly Hills, CA, USA |
| |
|
PCN8 |
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): THE ITALIAN CASE |
|
Esposito G1, Lamotte M1, Annemans L2, Bracco A3 |
|
1IMS Health, Brussels, Belgium, 2Ghent University, Gent, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland |
| |
|
PCN9 |
COST-EFFECTIVENESS OF SUPERFICIAL BLADDER CANCER SURVEILLANCE IN WHICH CYSTOSCOPY IS PARTLY REPLACED BY MICROSATELLITE ANALYSIS |
|
De Bekker-Grob EW1, Van der Aa MNM2, Zwarthoff EC1, Meerding WJ1, Eijkemans MJC1, Van Rhijn BWG1, Van der Kwast TH3, Steyerberg EW1 |
|
1Erasmus MC, Rotterdam, The Netherlands, 2LUMC, Leiden, The Netherlands, 3Mount Sinai Hospital, Toronto, ON, Canada |
| |
|
PCN10 |
COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN |
|
Hsia TC1, Chang GC2, Chen YM3, Lin MC4, Su WC5, Tsai CM3, Tsai CM6, Yang L7, Creeden J8 |
|
1China Medical University Hospital, Taichung, Taiwan, 2Taichung Veterans General Hospital, Taichung, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Chang Guang Memorial Hospital, Kaohsiung Branch, Kaohsiung, Taiwan, 5National Cheng Kung University Hospital, Tainan, Taiwan, 6Roche Taiwan, Taipei, Taiwan, 7Roche Products Ltd, Taipei, Taiwan, 8F Hoffmann La Roche, Basel, Switzerland |
| |
|
PCN11 |
COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA |
|
Logman JFS1, Taylor MJ2, Neumann K3, Kutikova L4, Cerri KH5, Van Hout BA1, Kühr T6 |
|
1Pharmerit Europe, Rotterdam, The Netherlands, 2University of York, York, UK, 3Vienna School of Evidence Based Medicine, Vienna, Austria, 4Bristol-Myers Squibb Central Europe, Prague, Czech Republic, 5Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 6Klinikum Kreuzschwestern, Wels, Austria |
| |
|
PCN12 |
COST-EFFECTIVENESS OF TARGETED ONCOLOGY THERAPIES: A SYSTEMATIC LITERATURE REVIEW |
|
Kalpas E, Doyle J |
|
Analytica International, New York, NY, USA |
| |
|
PCN13 |
ASSESSMENT OF THE COST-EFFECTIVENESS IN AUSTRALIA OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CANCERS OF THE HEAD AND NECK |
|
De Abreu Lourenco R1, Houltram J1, Pearce G2 |
|
1Covance, North Ryde, New South Wales, Australia, 2Alphapharm Pty Limited, Glebe, New South Wales, Australia |
| |
|
PCN14 |
COST-EFFECTIVENESS OF EXEMESTANE VS. TAMOXIFEN IN POST-MENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN GERMANY |
|
Braun S1, Mittendorf T1, Greiner W2, Dopatka J3, von der Schulenburg JM1 |
|
1Leibniz University of Hannover, Hannover, Germany, 2University of Bielefeld, Bielefeld, Germany, 3Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
PCN15 |
ESTIMATING THE COST EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN IRELAND USING A MATHEMATICAL MODEL |
|
Redmond S1, Demarteau N2 |
|
1GlaxoSmithKline, Dublin 16, Ireland, 2IMS HEOR, Brussels, Belgium |
| |
|
PCN16 |
COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN |
|
Chao TY1, Chen SC2, Chang KJ3, Chang HK4, Chen DR5, Hou MF6, Hsieh RK7, Huang WT8, Tseng LM9, Wang HC10, Yang L11, Cirrincione A12 |
|
1Tri-Service General Hospital, Taipei, Taiwan, 2Chang Guang Memorial Hospital, Taipei Branch, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan, 4Chang Guang Memorial Hospital, Linkou Branch, Linkou, Taiwan, 5Changhua Christian Hospital, Changhua, Taiwan, 6Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 7Mackay Memorial Hospital, Taipei, Taiwan, 8Chimei Medical Center, Tainan, Taiwan, 9Taipei Veterans General Hospital, Taipei, Taiwan, 10China Medical University Hospital, Taichung, Taiwan, 11Roche Products Ltd, Taipei, Taiwan, 12F.Hoffmann-La Roche Ltd, Basel, Switzerland |
| |
|
PCN17 |
COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL |
|
Correa M1, Perdicaris M2, Vernaglia PRW3, Da Cunha FM4, Saggia MG5, Santos EA5, Nasciben V5 |
|
1Hospital do Cancer A. C. Camargo, Sao Paulo, SP, Brazil, 2Hospital Beneficência Portuguesa, Santos, SP, Brazil, 3Brazilian Institute for Cancer Control - IBCC, Sao Paulo, SP, Brazil, 4Centro médico de Campinas, Campinas, SP, Brazil, 5Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN18 |
SUNITINIB VS. INTERFERON-ALPHA (IFN-Α) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC): AN ECONOMIC EVALUATION |
|
Remák E1, Brown R2, Negrier S3, Motzer RJ4, Kim ST5, Charbonneau C6 |
|
1United Biosource Corporation, Budapest, Hungary, 2United BioSource Corporation, London, London, UK, 3Centre Leron Berard, Lyon, France, 4Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Pfizer Inc, San Diego, CA, USA, 6Pfizer Inc, New York, NY, USA |
| |
|
PCN19 |
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): THE GERMAN CASE |
|
Van Bellinghen LA1, Esposito G2, Lamotte M2, Bracco A3, Goertz A4, Annemans L5 |
|
1IMS HEOR, Brussels, Belgium, 2IMS Health, Brussels, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland, 4Amgen Germany GmbH, Munich, Germany, 5Ghent University, Gent, Belgium |
| |
|
PCN20 |
COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN THE UK |
|
Brown B1, Tilden D1, Griebsch I2, Ralston SJ3 |
|
1IMS Health, London, UK, 2Merck KGaA, Darmstadt, Germany, 3Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN21 |
A HEALTH ECONOMIC EVALUATION OF HEXVIX AS ADJUNCT TO STANDARD WHITE LIGHT CYSTOSCOPY IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER |
|
Demarteau N1, Braeckman J2, Michielsen D2, Sweet A3, Zyczynski T4, Lamotte M5 |
|
1IMS HEOR, Brussels, Belgium, 2AZ-VUB, Brussels, Belgium, 3GE Healthcare, Buckinghamshire, UK, 4GE Healthcare, Princeton, NJ, USA, 5IMS Health, Brussel, Brabant, Belgium |
| |
|
PCN22 |
COST-EFFECTIVENESS OF SUNITINIB AS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUM |
|
Van Nooten F1, Dewilde S1, Van Belle S2, Marbaix S3 |
|
1United BioSource Corporation, Brussels, Belgium, 2University Hospital Ghent, Gent, Belgium, 3Pfizer, Brussels, Belgium |
| |
|
PCN23 |
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN ITALY |
|
Chiroli S1, Ciceri DF2, Atchison C3, Malin JL4, Liu Z5, Doan QV5, Dubois RW5 |
|
1Amgen, Milan, Italy, 2Istituto Scientifico San Raffaele, Milano, Italy, 3Amgen (Europe) Gmbh, Zug, Switzerland, 4Amgen Inc, Thousand Oaks, CA, USA, 5Cerner Corporation, Beverly Hills, CA, USA |
| |
|
PCN24 |
COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING |
|
Ruiz MA1, Garrido J1, García Pulgar M2, Alvarez Sanz C2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Roche Farma, Madrid, Spain |
| |
|
PCN25 |
PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UK |
|
Cowell W, Summerhayes M |
|
Roche Products Ltd, Welwyn Garden City, UK |
| |
|
PCN26 |
INNOVATION OVER THE PRODUCT LIFE CYCLE: ESTIMATING THE POTENTIAL ECONOMIC VALUE OF TRASTUZUMAB IN BREAST CANCER IN FIVE EUROPEAN COUNTRIES BETWEEN 2000 AND 2020 |
|
Garrison LP, Veenstra DL |
|
University of Washington, Seattle, WA, USA |
| |
|
PCN27 |
COST-EFFECTIVENESS OF HUMAN INTERFERON-ALPHA AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED CUTANEOUS MALIGNANT MELANOMA IN STAGE IIB & III |
|
Kasteng F1, Stadler R2, Wagenius G3, Lundkvist J1 |
|
1i3 Innovus, Stockholm, Sweden, 2Academic Medical Centre, Minden, Germany, 3Uppsala University Hospital, Uppsala, Sweden |
| |
|
PCN28 |
ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2–3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER: A FINNISH PERSPECTIVE |
|
Färkkilä N1, Kotomäki T2, Jormanainen V2 |
|
1Karolinska Institutet, Stockholm, Sweden, 2Pfizer Oy, Helsinki, Finland |
| |
|
PCN29 |
COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN |
|
Kasteng F1, Erlanson M2, Hagberg H3, Kimby E4, Relander T5, Lundkvist J1 |
|
1i3 Innovus, Stockholm, Sweden, 2Umeå University Hospital, Umeå, Sweden, 3Uppsala University Hospital, Uppsala, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5Lund University Hospital, Lund, Sweden |
| |
|
PCN30 |
THE ECONOMIC BENEFITS OF TEGAFUR WITH URACIL (UFTORAL) IN FIRST- LINE METASTATIC COLORECTAL CANCER |
|
Ralston SJ, Almond J |
|
Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN31 |
COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IV AS FIRST LINE THERAPY FOR ADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE |
|
Malzyner A1, Saggia MG2, Nasciben V2 |
|
1Hospital Brigadeiro da Secretaria da Saúde do Estado de São Paulo, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN32 |
COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL |
|
Stefani S1, Saggia MG2, Santos EA2 |
|
1UNIMED and Instituto do Câncer Mãe de Deus, Porto Alegre, RS, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN33 |
COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL |
|
Lago S1, Nasciben V2, Saggia MG2 |
|
1PUC-RS, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN34 |
COST MINIMIZATION ANALYSIS OF INTRA-VENOUS BIPHOSPHONATES THERAPIES AVAILABLE IN BRAZIL FOR THE PROPHYLAXIS OF SKELETAL EVENTS (SE) IN BREAST CANCER PATIENTS WITH BONE METASTASIS |
|
Perdicaris M1, Nasciben V2, Saggia MG2 |
|
1Hospital Beneficência Portuguesa, Santos, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN35 |
ASSESSING THE IMPACT ON STAFF RESOURCES AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY WITH VINORELBINE |
|
Colombo GL1, Caruggi M2, Ottolini C3, Cortinovis D4 |
|
1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Milano, Italy, 2Università dell'Insubria, Varese, Italy, 3Azienda Ospedaliera di Busto Arsizio, Varese, Busto Arsizio, Varese, Italy, 4Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy |
| |
|
PCN36 |
ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXED AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON–SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS |
|
Capri S1, Morabito A2, Carillio G3, Grossi F4, Longo R5, Cerea G6, Rossetti F7 |
|
1Cattaneo-LIUC University, Castellanza, (Varese), Italy, 2Istituto Nazionale Tumori, Napoli, NA, Italy, 3Humanitas Centro Catanese di Oncologia, Catania, CA, Italy, 4Istituto Nazionale per la Ricerca sul Cancro, Genova, GE, Italy, 5San Filippo Neri, Roma, RM, Italy, 6Ospedale Niguarda Ca’ Granda, Milano, MI, Italy, 7ROCHE S.p.A, Monza, MZ, Italy |
| |
|
PCN37 |
RESOURCE USE AND TIME SAVINGS IN SPAIN LINKED WITH NEW CHEMOTHERAPY PRESENTATIONS: THE CASE OF OXALIPLATIN |
|
Betegon L1, Echevarria A2, Soler F3, Quer N3 |
|
1IMS HEOR, Madrid, Spain, 2sanofi-aventis, Madrid, Spain, 3Institut Català d’Oncologia Girona, Girona, Spain |
| |
|
PCN38 |
COST-ANALYSIS OF XELOX VS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING |
|
Garrison L1, Giuliani G2, Ducournau P3, Cirrincione A3 |
|
1University of Washington, Seattle, WA, USA, 2Roche S.p.A. Italy, Monza, Italy, 3F. Hoffmann-La Roche, Basel, Switzerland |
| |
|
PCN39 |
THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND |
|
Rash B1, Prendiville W2, Byrne P3, Stratton J4, Redmond S5 |
|
1Health Market International, Ann Arbor, MI, USA, 2Coombe Women's Hospital, Dublin, Ireland, 3Beaumont Hospital, Dublin, Ireland, 4Waterford Regional Hospital, Waterford, Ireland, 5GlaxoSmithKline, Dublin 16, Ireland |
| |
|
PCN40 |
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT: AN ECONOMIC MODEL OF THE IMPACT ON GERMAN HEALTH CARE COSTS |
|
Sievert KD1, Zyczynski T2, Sweet A3, Rößler DW4, Stenzl A5 |
|
1Universitätsklinikum Tübingen, Tübingen, Germany, 2GE Healthcare, Princeton, NJ, USA, 3GE Healthcare, Buckinghamshire, UK, 4Caritas-Krankenhaus St. Josef, Regensburg, Germany, 5University of Tuebingen, Tübingen, Germany |
| |
|
PCN41 |
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT: AN ECONOMIC MODEL OF THE IMPACT ON HEALTHCARE COSTS IN THE UK |
|
Zyczynski T1, Sweet A2, Wallace DM3 |
|
1GE Healthcare, Princeton, NJ, USA, 2GE Healthcare, Buckinghamshire, UK, 3Queen Elizabeth Medical Centre, Birmingham, UK |
| |
|
PCN42 |
COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS: A GERMAN HOSPITAL PERSPECTIVE |
|
Paessens B1, Berger K2, Ihbe-Heffinger A1, Mueller-Thomas C1, Shlaen M3, Von Schilling C4, Bernard R1, Peschel C1, Schramm W2 |
|
1Klinikum rechts der Isar der Technischen Universität München, München, Germany, 2University Hospital of Munich, München, Germany, 3Medical Economic Research Group (MERG), München, Germany, 4Klinikum Freising, Freising, Germany |
| |
|
PCN43 |
COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER |
|
Lundkvist J1, Kasteng F1, Lindman H2, Wilking N3 |
|
1i3 Innovus, Stockholm, Sweden, 2Uppsala University Hospital, Uppsala, Sweden, 3Karolinska Institute, Stockholm, Sweden |
| |
|
PCN44 |
ADJUVANT TRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER: COST-EFFECTIVENESS IN THE BELGIAN HEALTHCARE SETTING |
|
Van Vlaenderen I1, Canon J2, Cocquyt V3, Jerusalem G4, Machiels J5, Neven P6, Nechelput M7, Delabaye I7, Gyldmark M8, Annemans L9 |
|
1IMS Health Belgium, Brussels, Brussels, Belgium, 2Centre Hospitalier Notre Dame et Reine Fabiola, Charleroi, Belgium, 3University Hospital Gent, Gent, Belgium, 4Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium, 5Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium, 6University Hospital Leuven, Leuven, Belgium, 7Roche Pharmaceuticals, Brussels, Belgium, 8F. Hoffmann - La Roche, Basel, Switzerland, 9Ghent University, Gent, Belgium |
| |
|
PCN45 |
UK COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS GENERIC PACLITAXEL ONCE WEEKLY AND NAB-PACLITAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY M |
|
Benedict Á1, Cameron D2, Corson H3, Jones S4 |
|
1United BioSource Corporation, Budapest, Hungary, 2University of Leeds, Leeds, UK, 3sanofi-aventis, Bagneux, France, 4US Oncology Research, Houston, TX, USA |
| |
|
PCN46 |
A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UK |
|
Geary U1, Lewis G2, Aultman R3, Aristides M4 |
|
1Roche Products Limited, Hertfordshire, UK, 2Roche Products Limited, Welwyn Garden City, Herts, UK, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4IMS Health, London, UK |
| |
|
PCN47 |
COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY |
|
Muszbek N1, Odhiambo R2 |
|
1UnitedBiosource Corporation, London, UK, 2sanofi-aventis Zrt, Budapest, Hungary |
| |
|
PCN48 |
SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) – AN ECONOMIC EVALUATION USING BAYESIAN APPROACH |
|
Purmonen T1, Martikainen JA1, Soini EJ2, Kataja V3, Kellokumpu-Lehtinen P4 |
|
1Centre for Pharmaceutical Policy and Economics (CEPPE), University of Kuopio, Kuopio, Finland, 2Centre for Pharmaceutical Policy and Economics (CEPPE) and Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, 3Kuopio University Hospital and Vaasa Central Hospital, Kuopio, Finland, 4Tampere University Hospital and University of Tampere, Tampere, Finland |
| |
|
PCN49 |
COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL |
|
Chiattone CS1, Saggia MG2, Santos EA2 |
|
1Faculdade de Ciências Médicas da Santa Casa de Sao Paulo, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN50 |
COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY |
|
Jozsa G |
|
University of West Hungary, Sopron, Hungary |
| |
|
PCN51 |
WITHDRAWN |
|
|
|
|
| |
|
PCN52 |
GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY |
|
Boncz I1, Péntek M2, Ágoston I1, Betlehem J1, Karpati K3, Brodszky V3, Gulácsi L3, Sebestyén A4 |
|
1University of Pécs, Pécs, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary |
| |
|
PCN53 |
EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN OVER 64 YEARS |
|
Boncz I1, Betlehem J1, Ember I1, Sebestyén A2 |
|
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration (OEP), Pécs, Hungary |
| |
|
PCN54 |
INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS: CZECH REPUBLIC LONG-TERM DATA |
|
Skoupá J1, Cerna V1, Doležal T2 |
|
1Pharma Projects, Prague, Czech Republic, 23-rd Medical Faculty Charles University, Prague, Czech Republic |
| |
|
PCN55 |
THE IMPACT OF 21-GENE RT-PCR ASSAY ON REAL LIFE TREATMENT DECISIONS IN N-, ER+ EARLY-STAGE BREAST CANCER PATIENTS: IT'S IMPLICATION FOR BUDGET IMPACT ANALYSIS |
|
Hammerman A1, Klang SH2, Liebermann N2, Efrat N3 |
|
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Clalit Health Services, Tel-Aviv, Israel, 3Kaplan Medical Center, Rehovot, Israel |
| |
|
PCN56 |
INTERNATIONAL INCIDENCE OF MEN WITH UNCERTAIN INDICATION FOR RADICAL PROSTATECTOMY: AN EVIDENCE-BASED ANALYSIS |
|
Lee DW1, Dann RA2, Lintner MJ1, Zhang B3, Friedman M3, Menzin J3 |
|
1GE Healthcare, Waukesha, WI, USA, 2GE Healthcare, Chalfont St Giles, UK, 3Boston Health Economics, Waltham, MA, USA |
| |
|
PCN57 |
BASIC ATTITUDE TO USE OF GENERIC ANTI-CANCER DRUGS FOR BREAST CANCER TREATMENT IN JAPAN |
|
Saito S1, Shimozuma K2, Ohashi Y3, Fukuda T3, Fukui N4, Mouri M4, Kuroi K5 |
|
1Kochi Women's University, Kochi, Japan, 2Ritsumeikan University, Kusatsu, Shiga, Japan, 3University of Tokyo, Bunkyo-ku, Tokyo, Japan, 4Japan Clinical Research Support Unit, Bunkyo-ku, Tokyo, Japan, 5Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan |
| |
|
PCN58 |
BREAST CANCER SCREENING PROGRAMS: EVALUATION ASIDE FROM CLINICAL AND ECONOMICAL ASPECTS |
|
Radlberger P |
|
Ludwig Boltzmann Institute of Health Technology Assessment, Vienna, Austria |
| |
|
PCN59 |
TREATMENT PATTERNS FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) IN GERMANY |
|
Jenkins A1, Aristides M1, Liepa AM2, Relf C3, Feilding B3 |
|
1IMS Health Economics and Outcomes Research, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3IMS Health, Sittingbourne, UK |
| |
|
PCN60 |
IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD |
|
Conner TM1, Beveridge R2, Lokay K3, Young D3, Johnston A3 |
|
1Outcomes Research Consulting, Austin, TX, USA, 2US Oncology, Fairfax, VA, USA, 3US Oncology, Houston, TX, USA |
| |
|
PCN61 |
MULTI-STATE SURVIVAL ANALYSIS IN COST-EFFECTIVENESS STUDIES: THE CASE OF CAPECITABINE VERSUS DOCETAXEL IN METASTATIC BREAST CANCER (MBC) FOR A PRIVATE PAYER IN BRAZIL |
|
Santos EA1, Marques RM2 |
|
1Roche Brazil, Sao Paulo, SP, Brazil, 2Hospital Sirio Libanês, São Paulo, São Paulo, Brazil |
| |
|
PCN62 |
USE OF A 5-LEVEL EQ-5D IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA |
|
Holtzer-Goor KM1, Thompson SL1, Schaafsma MR2, Uyl-de Groot C1 |
|
1institute for Medical Technology Assessment, Rotterdam, Zuid-Holland, The Netherlands, 2Medisch Spectrum Twente, Enschede, The Netherlands |
| |
|
PCN63 |
META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER |
|
Miksad R1, Zietemann V2, Mattheucci Gothe R2, Schwarzer R2, Conrads-Frank A2, Schnell-Inderst P2, Stollenwerk B2, Plieschnegger P2, Esteban E2, Siebert U2 |
|
1Beth Israel Deaconess Medical Center / Institute for Technology Assessment / Harvard University, Boston, MA, USA, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Hall, Tirol, Austria |
| |
|
PCN64 |
CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN) |
|
Mallick R1, Hudes G2, Levy DE3 |
|
1Wyeth Research, Collegeville, PA, USA, 2Fox Chase Cancer Center, Philadelphia, PA, USA, 3Wyeth Pharmaceuticals, Cambridge, MA, USA |
| |
|
PCN65 |
RESULTS FROM MABEL: QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC) |
|
Glynne - Jones R1, Esser R2, Ralston SJ3 |
|
1Mount Vernon Hospital, Northwood, Middlesex, UK, 2Merck KGaA, Darmstadt, Germany, 3Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN66 |
DEFINING HEALTH STATE UTILITIES FOR HAND-FOOT-SYNDROME |
|
Roth S1, Simons S1, Güney D1, Reineking N1, Dietrich ES2, Jaehde U1 |
|
1University of Bonn, Bonn, NRW, Germany, 2TK Scientific Institute for Benefit and Efficiency in Health Care, Hamburg, Germany |
| |
|
PCN67 |
ESTIMATION OF IMPORTANT DIFFERENCES IN EQ-5D VAS SCORES IN CANCER |
|
Pickard AS1, Neary MP2, Cella D3 |
|
1College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 2GlaxoSmithKline, Collegeville, PA, USA, 3Evanston Northwestern Healthcare, Evanston, IL, USA |
| |
|
PCN68 |
SENSITIVITY TO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE |
|
Baro E1, Cassinello J2, Carulla J3, Valentín V4, Rodríguez C5, Gascón P6, García-Mata J7, Colomer R8, Gasquet JA9, Perform group G10 |
|
13D Health Research, Barcelona, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3Hospital Verge del Toro, Menorca, Spain, 4Hospital 12 de octubre, Madrid, Spain, 5Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 6Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 7Hospital Santa Maria Nai, Orense, Spain, 8Centro Oncológico MD Anderson, Madrid, Spain, 9AMGEN S.A, Barcelona, Spain, 10The PERFORM Study Group, Barcelona, Spain |
| |
|
PCN69 |
PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL |
|
Mallick R1, Sun S1, Hudes G2 |
|
1Wyeth Research, Collegeville, PA, USA, 2Fox Chase Cancer Center, Philadelphia, PA, USA |
| |
|
PCN70 |
UTILITY VALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML): ESTIMATES FROM LAYPERSONS IN AUSTRALIA, THE UK (UK) AND CANADA |
|
Levy AR1, Szabo SM1, Tabberer M2, Davis C3 |
|
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Oxford Outcomes Ltd, Oxford, Oxon, UK, 3Bristol-Myers Squibb, Wallingford, CT, USA |
| |
|
PCN71 |
CONJOINT ANALYSIS A TECHNIQUE TO DEVELOP A QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH LUNG CANCER |
|
Perulero N1, Cardenal F2, Garcia R3, Juan O4, Vázquez S5, Barneto I6, Varela C7 |
|
1IMS Health, Barcelona, Spain, 2ICO. Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain, 3Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Hospital Arnau de Vilanova, Valencia, Spain, 5Complexo Hospitalario Xeral Calde, Lugo, Spain, 6Hospital General Universitario Reina Sofía, Córdoba, Spain, 7Roche Farma, Madrid, Spain |
| |
|
PCN72 |
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND KIDNEY CANCER-RELATED SYMPTOMS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA IN A RANDOMISED, MULTINATIONAL PHASE III TRIAL: RESULTS FOR EUROPEAN AND US SUBSAMPLE ANALYSES |
|
Cella D1, Li JZ2, Bushmakin AG3, Cappelleri JC4, Kim ST2, Chen I2, Charbonneau C5, Motzer RJ6 |
|
1Evanston Northwestern Healthcare, Evanston, IL, USA, 2Pfizer Inc, San Diego, CA, USA, 3Pfizer, Inc, Groton, CT, USA, 4Pfizer Inc, Groton, CT, USA, 5Pfizer Inc, New York, NY, USA, 6Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| |
|
PCN73 |
LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES |
|
Eremenco S1, Arnold B1, Weinstein D2, Sendersky V2 |
|
1Evanston Northwestern Healthcare, Evanston, IL, USA, 2Ferring Pharmaceuticals, Copenhagen, Denmark |
| |
|
PCN74 |
PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING: ADAPTATION OF A QUESTIONNAIRE |
|
Thorsen H, Brodersen J |
|
University of Copenhagen, Copenhagen, Denmark |
| |
|
PCN75 |
WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT? |
|
Ramsey SD1, Zeliadt SD1, Hall IJ2, Lee JW2, Ekwueme DU2, Moinpour CM1, Penson D3 |
|
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA, 3University of Southern California / Norris Cancer Center, Los Angeles, CA, USA |
| |
|
PCN76 |
COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT |
|
Marshall DA1, Johnson FR2, Kulin NA1, Ozdemir S2, Marshall JK1, Walsh J3, Van Bebber S3, Phillips KA3 |
|
1McMaster University, Hamilton, ON, Canada, 2RTI International, Research Triangle Park, NC, USA, 3University of California, San Francisco, San Francisco, CA, USA |
| |
|
PCN77 |
PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL-CELL LUNG CANCER (NSCLC) IN TURKEY |
| |
Batigun O, Yildirim E |
|
Roche Müstahzarlari Sanayi AS, Istanbul, Maslak-Istanbul, Turkey |
EYE
PEY1 |
USE OF BAYESIAN NETWORKS TO SPECIFY NOCTURNAL IOP CONTROL BY PROSTAGLANDIN ANALOGUES ACCORDING TO SEVERAL THRESHOLDS FROM DAY-TIME MEASUREMENTS IN GLAUCOMA PATIENTS |
|
Nordmann JP1, Berdeaux G2 |
|
1Centre Hospitalier National des Quinze-Vingts, Paris, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
PEY2 |
INTRA-OCULAR PRESSURE CONTROL OF XALACOM ® (FIXED LATANOPROST AND TIMOLOL COMBINATION) AND DUOTRAV ® (FIXED TRAVOPROST AND TIMOLOL COMBINATION) IN DAILY PRACTICE |
|
Lafuma A1, Jeanbat V1, Laurendeau C1, Berdeaux G2 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
PEY3 |
RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM |
|
Neubauer AS1, Back EI2, Kuehn T2, Thomas VS3 |
|
1Eye Hospital of the Ludwig-Maximilians-University, Munich, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany, 3Novartis Pharma AG, Basel, Switzerland |
| |
|
PEY4 |
COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES |
|
Hommer AB1, Friis M2, Wickstrom J2, Poulsen PB2, Walt JG3, Buchholz P4 |
|
1Krankenhaus Hera Vienna, Vienna, Austria, 2MUUSMANN Research & Consulting A/S, Kolding, Denmark, 3Allergan Inc, Irvine, CA, USA, 4Allergan Europe, Ettlingen, Germany |
| |
|
PEY5 |
COST-EFFECTIVENESS MODELING OF LUCENTIS VERSUS USUAL CARE IN AGE RELATED MACULAR DEGENERESCENCE |
|
Beresniak A1, Cohen S2, Quentel G2, Mimoun G3, Citterio T4, Bremond-Gignac D5 |
|
1Data Mining International, Geneva, Switzerland, 2Imaging and Laser centre, Paris, France, 3Eye Medical Centre, Paris, France, 4Novartis Pharmaceuticals, Rueil-Malmaison, France, 5Robert Debre Hospital, Paris, France |
| |
|
PEY6 |
COST OF CATARACT SURGERY AFTER IMPLANTATION OF THREE INTRAOCULAR LENSES WITH SQUARE EDGES |
|
Smith AF1, Lafuma A2, Jeanbat V2, Boureau C3, Dubois V4 |
|
1Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, 2Cemka-Eval, Bourg-la-Reine, France, 3Ophthalmologist, Paris, France, 4Laboratoire Alcon, Rueil Malmaison, France |
| |
|
PEY7 |
BELGIAN COST-UTILITY ANALYSIS OF LUCENTIS (RANIBIZUMAB) IN WET AGE RELATED MACULAR DEGENERATION
|
|
Moeremans K1, Annemans L2, Lecomte P3 |
|
1IMS Health, Brussel, Belgium, 2Ghent University, Ghent, Belgium, 3Novartis Pharmaceuticals, Vilvoorde, Belgium |
| |
|
PEY8 |
A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES |
|
Lafuma A1, Laurendeau C1, Lamerain E2, Berdeaux G3 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2TNS Sofres, Montrouge, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
PEY9 |
COST OF STANDARD CARE TREATMENT IN THE UK AMONG PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA |
|
Walt JG1, Chiang TH1, Stern L2, Doyle J2, Berenson K2 |
|
1Allergan Inc, Irvine, CA, USA, 2Analytica International, New York, NY, USA |
| |
|
PEY10 |
OXIDATIVE STRESS IN ADVANCED PRIMARY OPEN-ANGLE GLAUCOMA |
|
Zanon-Moreno V1, Pons S1, Garcia-Medina JJ2, Gallego-Pinazo R3, Vinuesa-Silva I4, Marco-Ventura P1, Pinazo-Duran M4 |
|
1Universitary Hospital Dr. Peset, Valencia, Spain, 2Hospital La Inmaculada, Huercal Overa, Almeria, Spain, 3Hospital La Fe, Valencia, Spain, 4Hospital Punta de Europa, Algeciras, Cadiz, Spain |
| |
|
PEY11 |
ESTIMATING NET HEALTH BENEFITS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD) |
|
Levy AR1, Szabo SM1, Zlateva G2, Briggs A3, Pleil A4 |
|
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Pfizer Inc, New York, NY, USA, 3University of Glasgow, Glasgow, UK, 4Pfizer Inc, San Diego, CA, USA |
| |
|
PEY12 |
METHODOLOGICAL ISSUES ARISING FROM THREE STUDIES WHICH INCLUDED CONJOINT ANALYSIS IN VISUALLY IMPAIRED PEOPLE |
|
Aspinall PA1, Brice R2, Vickers A2, Steeds CS3, Buchholz P4 |
|
1Heriot-Watt University, Edinburgh, UK, 2Adelphi Group Ltd, Bollington, Cheshire, UK, 3CS Consulting, Motherwell, Scotland, UK, 4Allergan Europe, Ettlingen, Germany |
| |
|
PEY13 |
TIME TO DISCONTINUATION OF GLAUCOMA MEDICINES PRESCRIBED SUBSEQUENT TO INITIAL THERAPY |
|
Montgomery DMI1, Witchalls A1, Pleil A2 |
|
1Glasgow Royal Infirmary, Glasgow, UK, 2Pfizer Inc, San Diego, CA, USA |
| |
|
PEY14 |
ASSESSMENT OF THE PERSISTENCE DEGREE IN PATIENTS WITH ANTIGLAUCOMA AGENTS AS FIRST LINE MONOTHERAPIES IN SPAIN |
|
Arias A1, Schargel K2, Ussa F3, Canut MI4, Martí B5, Soto J6 |
|
1Hospital de Alcorcón, Alcorcón, Madrid, Spain, 2Hospital de Torrevieja, Torrevieja, Alicante, Spain, 3Instituto Universitario de Oftalmobiología Aplicada, Valladolid, Spain, 4Centro de Oftalmología Barraquer, Barcelona, Spain, 5Universidad Autónoma de Madrid, Madrid, Madrid, Spain, 6Pfizer Spain, Madrid, Spain |
| |
|
PEY15 |
HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE |
|
Soubrane G1, Zlateva G2, Xu X3, Goss TF3, Buggage R2, Kosa M4 |
|
1Centre Hospitalier Intercommunal de Créteil, Créteil, France, 2Pfizer Inc, New York, NY, USA, 3Covance Market Access Services, Gaithersburg, MD, USA, 4Pfizer, Paris, France |
| |
|
PEY16 |
CULTURAL ADAPTATION AND PARTIAL VALIDATION OF THE GLAUCOMA SYMPTOM SCALE (GSS) TO SPANISH |
|
Ruiz MA1, Pardo A1, Martínez de la Casa JM2, Polo V3, Esquirol J4, Soto J5, Jiménez S6 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Fundación Hospital Alcorcón, Madrid, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Centro Médico Tecnón, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain, 6Pfizer España, Madrid, Spain |
|
|
GI DISORDERS
PGI1 |
DETERMINATION OF MINIMAL IMPORTANT DIFFERENCES (MIDS) AND INTERPRETATION OF SF-36 SCORES IN PATIENTS SUFFERING FROM MODERATE-TO-SEVERE CROHN'S DISEASE |
|
Keininger D1, Feagan BG2, Coteur G3, Kosinski M4 |
|
1UCB S.A, Braine-l’Alleud, Belgium, 2Robarts Research Institute, London, Ontario, Canada, 3SGS Life Sciences, Mechelen, Belgium, 4QualityMetric Incorporated, Lincoln, RI, USA |
| |
|
PGI2 |
PROTON PUMP INHIBITORS FOR THE INITIAL TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMS IN PATIENTS WITH REFLUX OESOPHAGITIS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS |
|
Edwards SJ, Borrill J |
|
AstraZeneca UK Ltd, Luton, UK |
| |
|
PGI3 |
BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE |
|
Trichard M, Largeron N, Soum S, Saint-Sardos C |
|
sanofi pasteur MSD, Lyon, France |
| |
|
PGI4 |
ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA |
|
Mason J1, Lloyd AC2, Holman AJ2, Jobanputra M3 |
|
1University of Durham, Queen's Campus, Stockton-on-Tees, Durham, UK, 2Fourth Hurdle Consulting, London, UK, 3Wyeth Pharmaceuticals, Maidenhead, Berkshire, UK |
| |
|
PGI5 |
EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DECISION-ANALYTIC MODEL |
|
Nielsen SK1, Connolly MP1, Bhatt A1, Currie CJ2 |
|
1Ferring International Center, Saint-Prex, Switzerland, 2Cardiff University, Cardiff, UK |
| |
|
PGI6 |
PHARMACOECONOMIC ANALYSIS OF PROTON PUMP INHIBITORS ON C & D ESOPHAGITIS TREATMENT IN SPAIN |
|
Cordero L1, Jimenez J1, Hernandez R2, Coll E1 |
|
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2AstraZeneca, Madrid, Spain |
| |
|
PGI7 |
COST-EFFECTIVENESS ANALYSIS OF TREATING CHORNIC HEPATITITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE |
|
Ravasio R1, Giuliani G2 |
|
1Wolters Kluwer Health, Milano, Italy, 2Roche S.p.A, Milano, Italy |
| |
|
PGI8 |
COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX OESOPHAGITIS |
|
Borrill J, Edwards SJ |
|
Astrazeneca UK Ltd, Luton, UK |
| |
|
PGI9 |
PHARMACOECONOMIC ANALYSIS OF GERD TREATMENT AFTER OMEPRAZOLE FAILURE IN SPAIN |
|
Cordero L1, Jimenez J1, Hernandez R2, Coll E1 |
|
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2AstraZeneca, Madrid, Spain |
|
|
PGI10 |
WITHDRAWN |
| |
|
PGI11 |
IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS ON OPIOID THERAPY |
|
Candrilli SD1, Iyer S2, Davis KL1 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Wyeth Research, Collegeville, PA, USA |
| |
|
PGI12 |
THE DUEC (DIGITAL ULCERS ECONOMIC COST) STUDY: ECONOMIC BURDEN OF DIGITAL ULCERS IN ITALIAN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS |
|
Lopatriello S1, Tiso F2, Cozzi F2, Punzi L2, Berto P1 |
|
1pbe consulting, Verona, Italy, 2Azienda Ospedaliera di Padova, Padova, Italy |
| |
|
PGI13 |
THE EPIDEMIOLOGY AND HEALTHCARE RESOURCE USE IN PATIENTS WITH CROHN'S DISEASE: A POPULATION BASED UK STUDY |
|
Woehl A1, Hawthorne AB2, Morgan CL1, Punekar Y3, McEwan P4 |
|
1Cardiff University, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 4Cardiff Research Consortium, Cardiff, UK |
| |
|
PGI14 |
THE EPIDEMIOLOGY AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ULCERATIVE COLITIS: A POPULATION BASED UK STUDY |
|
Woehl A1, Hawthorne AB2, Morgan CL1, Punekar Y3, McEwan P4 |
|
1Cardiff University, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 4Cardiff Research Consortium, Cardiff, UK |
| |
|
PGI15 |
PERSISTENCE WITH INFLIXIMAB THERAPY REDUCES CROHN'S DISEASE RELATED MEDICAL COSTS |
|
Thompson HC1, Rahman MI1, Meissner B2, Tang B1, Dabbous O1 |
|
1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA |
| |
|
PGI16 |
AN EXPLORATORY ANALYSIS OF HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH PEDIATRIC CROHN'S DISEASE |
|
Thompson HC1, Teng E2, Rahman MI1, Ferrer R2, Tang B1, Dabbous O1, Pulicharam RJ3 |
|
1Centocor, Inc, Horsham, PA, USA, 2HealthCare Partners Corporate, Torrance, CA, USA, 3HealthCare Partners LA, Los Angeles, CA, USA |
| |
|
PGI17 |
INCREASED INPATIENT UTILIZATION FOLLOWING COLECTOMY IN ULCERATIVE COLITIS IN THE MEDICARE POPULATION |
|
Thompson HC1, Kugel MR2, Rahman MI1, Watson GJ2, Dabbous O1, Tang B1 |
|
1Centocor, Inc, Horsham, PA, USA, 2The Moran Company, Arlington, VA, USA |
| |
|
PGI18 |
THE QUALITY INDICATORS OF NURSING CARE AMONG PATIENTS WITH ACUTE PANCREATITIS IN HUNGARY |
|
Betlehem J1, Oláh A1, Boncz I1, Sebestyén A2, Aradan M1 |
|
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, Hungary |
| |
|
PGI19 |
INVESTIGATION OF OTC NSNSAID RATIONAL USE AND GASTROINTESTINAL DISEASES |
|
Petric M1, Tasic L1, Sukljevic S2 |
|
1University of Belgrade , Faculty of Pharmacy, Belgrade, Serbia, Serbia and Montenegro, 2The Public Pharmacy, Pozarevac, Serbia, Serbia and Montenegro |
| |
|
PGI20 |
MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZATION AND SURGERY IN CROHN'S DISEASE |
|
Thompson HC1, Pesa J2, Zhao N3, Han C3, Rahman MI1, Tang B1, Dabbous O1 |
|
1Centocor, Inc, Horsham, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO, USA, 3Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA |
| |
|
PGI21 |
THE VALUE OF INFORMATION OF SCREENING FOR HEREDITARY HEMOCHROMATOSIS |
|
Rogowski W |
|
GSF - National Research Center for Environment and Health, Neuherberg, Bavaria, Germany |
| |
|
PGI22 |
ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND UTILITY SCORES FROM EQ-5D OR SF-6D IN CROHN'S DISEASE |
|
Gerlier LC1, Brown M2, Tan SC2 |
|
1Keyrus Biopharma, Levallois-Perret, France, 2UCB, Slough, Berkshire, UK |
| |
|
PGI23 |
WITHDRAWN |
|
|
|
|
| |
|
PGI24 |
SPANISH CULTURAL ADAPTATION AND VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) |
|
Ruiz MArong>Ruiz MA1, Pardo A1, González P2, García M2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain |
| |
|
PGI25 |
DEVELOPMENT AND VALIDATION OF PATIENT REPORTED OUTCOMES MEASUREMENT SCALES FOR CROHN'S DISEASE: THE INFLAMMATORY BOWEL DISEASE IMPACT AND SYMPTOM SCALES (IBDIMSYS) |
|
Rauchensteiner S1, Miltenburger C2, Schaefer M3 |
|
1Charité Universitaetsmedizin Berlin, Berlin, Germany, 2Bayer Schering Pharma AG, Berlin, Germany, 3Institut für Klinische Pharmakologie, Berlin, Germany |
| |
|
PGI26 |
VALIDATED MEASURES OF HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY IN A POPULATION OF PATIENTS REPORTING CHRONIC CONSTIPATION |
|
Bolge SC1, Baran RW2 |
|
1Consumer Health Sciences, Princeton, NJ, USA, 2Takeda Global Research and Development Center, Inc, Deerfield, IL, USA |
| |
|
PGI27 |
ESTIMATION OF WEIGHTS FOR THE SPANISH VERSION OF SF-6D TO DERIVE SOCIETAL HEALTH STATE VALUES USING THE SPANISH VERSION OF SF-36V1 |
|
Ruiz MA1, Rejas J2, Pardo A1, Valdés C3, Ortega T3, Soto J2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain, 3Hospital Universitario Central de Asturias, Oviedo, Spain |
| |
|
PGI28 |
IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN'S DISEASE |
|
Tan SC1, Gerlier LC2, Brown M1 |
|
1UCB, Slough, Berkshire, UK, 2Keyrus Biopharma, Levallois-Perret, France |
| |
|
PGI29 |
UPPER GI SYMPTOMS IN GREEK PATIENTS RECEIVING ASPIRIN/NSAIDS |
|
Papatheodoridis G1, Vaskantiras V2, Daskos G2, Christodoulopoulou A2 |
|
1Ippokration General Hospital, Athens, Greece, 2AstraZeneca SA, Athens, Greece |
|
|
HEALTH CARE USE & POLICY STUDIES
PHP1 |
ECONOMIC ANALYSIS OF THE BAVARIAN BLOOD AND PLASMA MARKET: LESSONS FOR THE FUTURE |
|
Rottenkolber D1, Berger K1, Petermann A2, Weinauer F2, Schramm W1 |
|
1University Hospital of Munich, Munich, Germany, 2Blutspendedienst des Bayerischen Roten Kreuzes gGmbH, Munich, Germany |
| |
|
PHP2 |
A DETERMINATION OF TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN THAILAND |
|
Chaikledkaew U, Lertpitakpong C, Thavornchareonsap M, Youngkong S, Praditsitthikorn N, Yothasamut J, Tantivess S, Teerawattananon Y |
|
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand |
| |
|
PHP3 |
BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN: A CASE STUDY FROM HUNGARY |
|
Boncz I1, Gulácsi L2, Sebestyén A3 |
|
1University of Pécs, Pécs, Hungary, 2Corvinus University of Budapest, Budapest, Hungary, 3National Health Insurance Fund Administration, Pécs, Hungary |
| |
|
PHP4 |
CANADIAN COMPETION DURING A U.S. GENERIC DRUG'S 180-DAY EXCLUSIVITY PERIOD |
|
Richards KM, Shepherd MD |
|
University of Texas at Austin, Austin, TX, USA |
| |
|
PHP5 |
DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE |
|
Kalo Z1, Herczeg B2, Katona K3 |
|
1Eotvos Lorand University, Budapest, Hungary, 2Semmelweis University, Budapest, Hungary, 3Szinapszis Market Research and Consulting Ltd, Budapest, Hungary |
| |
|
PHP6 |
NETWORKING TOWARDS FUNCTIONAL POLICY-TOOLS: CAN CONDITIONAL REIMBURSEMENT OF DRUGS LEAD TO EFFICIENT AND EFFECTIVE DRUG USE? |
|
Niezen MGH, De Bont A, Stolk EA |
|
Erasmus Medical Center, Rotterdam, The Netherlands |
| |
|
PHP7 |
INTERNATIONAL COMPARISON OF GENERIC MEDICINE PRICES |
|
Simoens S |
|
Katholieke Universiteit Leuven, Leuven, Belgium |
| |
|
PHP8 |
THE CHALLENGE OF A LEGITIMATE BUDGET IMPACT RATIONING CRITERION IN DRUG REIMBURSEMENT DECISIONS |
|
Niezen MGH1, Cohen JP2, Stolk EA1, Busschbach JJ1 |
|
1Erasmus Medical Center, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands |
| |
|
PHP9 |
INFLUENCE OF POLYPHARMACY BY APPLYING THE ADJUSTED CLINICAL GROUPS CLASSIFICATION IN A SPANISH POPULATION SETTING: A CROSS-SECTIONAL STUDY |
|
Sicras-Mainar A1, Frías-Garrido X1, Ruano-Ruano I2, Navarro-Artieda R3, Velasco-Velasco S1, Llopart J1, Llausí-Sellés R2 |
|
1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Regió Sanitaria Barcelona. CatSalut, Badalona, Barcelona, Spain, 3Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain |
| |
|
PHP10 |
COMPLEMENT OR SUBSTITUTE? COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND PRESCRIPTION DRUG USE AMONG AFRICAN AMERICANS |
|
Richards KM, Brown CM, Barner J, Bohman T |
|
University of Texas at Austin, Austin, TX, USA |
| |
|
PHP11 |
EFFICIENCY IN DRUG PRESCRIPTION MEASURED BY THE APPLICATION OF ADJUSTED CLINICAL GROUPS IN FIVE SPANISH PRIMARY CARE CENTRES |
|
Sicras-Mainar A1, Navarro-Artieda R2, Ruano-Ruano I3, Velasco-Velasco S1, Frías-Garrido X1, Llopart J1, Llausí-Sellés R3 |
|
1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 3Regió Sanitaria Barcelona. CatSalut, Badalona, Barcelona, Spain |
| |
|
PHP12 |
RETROSPECTIVE DRUG UTILIZATION REVIEW: IMPACT OF PHARMACIST INTERVENTIONS ON PHYSICIAN PRESCRIBING |
|
Angalakuditi MV1, Gomes J2 |
|
1Convatec, A Bristol-Myers Squibb Company, Skillman, NJ, USA, 2UCB, Antioch, IL, USA |
| |
|
PHP13 |
THE COST OF WASTED MEDICINES IN PORTUGAL |
|
Mendes Z1, Crisostomo S2, Martins AP3, Batel Marques F4, Rodrigues V5, Fontes Ribeiro C5 |
|
1CEFAR, Lisbon, Portugal, 2Medtronic, Lda, Lisbon, Portugal, 3University of Lisbon, Lisbon, Portugal, 4Centre for Health Studies and Research, School of Economics and School of Pharmacy - University of Coimbra, Coimbra, Portugal, 5School of Medicine - University of Coimbra, Coimbra, Portugal |
| |
|
PHP14 |
GENERIC PRESCRIPTION MEDICINES PRICE VARIATION AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE |
|
Gavaza P1, Maponga CC2, Mukosera KT2 |
|
1University of Texas at Austin, Austin, TX, USA, 2University of Zimbabwe, Harare, Zimbabwe |
| |
|
PHP15 |
PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS |
|
Lim MK, Bae EY |
|
Health Insurance Review Agency, Seoul, Seocho-Gu, South Korea |
| |
|
PHP16 |
ASSESSMENT OF DECISION MAKER NEEDS RELATED TO HEALTH ECONOMIC MODELS AND DATA ANALYSIS TOOLS |
|
Olson BM, Lising A, Pijuan P, Fazio L, Baluta J, Hwang P |
|
Dymaxium Inc, Toronto, ON, Canada |
| |
|
PHP17 |
RECOMMENDATIONS FROM REIMBURSEMENT AGENCIES FOR ADDITIONAL POST-LAUNCH RESEARCH. THE NEXT HURDLE |
|
Marshall D1, Yong HE1, MacLeod S2, Drummond MF3 |
|
1i3 Innovus, Burlington, ON, Canada, 2British Columbia Child & Family Research Institute, Vancouver, BC, Canada, 3University of York, York, Heslington, UK |
| |
|
PHP18 |
HEALTH CARE DECISION-MAKERS' ATTITUDE ON HEALTH ECONOMICS RESEARCH |
|
Galani Berardo C |
|
Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands |
| |
|
PHP19 |
IMMUNIZATION PROGRAM IN PARAGUAY: SOCIAL AND BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL IMPACT |
|
Maceira DA |
|
Center for the Study of the State and Society, Buenos Aires, Argentina |
| |
|
PHP20 |
THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE |
|
Meerding WJ, Mackenbach J |
|
Erasmus MC, Rotterdam, The Netherlands |
| |
|
PHP21 |
IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION |
|
Shah ND, Banerjee R |
|
Mayo Clinic, Rochester, MN, USA |
| |
|
PHP22 |
THE GREEK PHARMACEUTICAL EXPENDITURE DATA: EFFECTS OF THE NATIONAL ACCOUNTS' REVISION |
|
Kousoulakou H1, Kyriopoulos J2 |
|
1Foundation for Economic and Industrial Research, Athens, Greece, 2National School of Public Health, Athens, Greece |
| |
|
PHP23 |
RELATIONSHIP BETWEEN RISKS FOR LIFESTYLE-RELATED DISEASES AND MEDICAL EXPENSES AFTER 10 YEARS OF METABOLIC SYNDROME |
|
Sakamaki H1, Kitazawa T2, Hasegawa T2 |
|
1Meijo University, Nagoya, Japan, 2Toho University School of Medicine, Tokyo, Japan |
| |
|
PHP24 |
WITHDRAWN |
|
|
|
|
| |
|
PHP25 |
MEDICATION ADHERENCE IN POST-TRANSPLANT IMMUNOSUPPRESSION: THE ECONOMIC IMPACT OF DRUG-REGIMEN COMPLEXITY |
|
Hansen R1, Seifeldin R2, Noe L1 |
|
1ICON Lifecycle Sciences Group, San Francisco, CA, USA, 2Astellas Pharma US, Inc, Deerfield, IL, USA |
| |
|
PHP26 |
THE EFFECT OF INJURY SEVERITY AND TRAUMA CENTER DESIGNATION ON INPATIENT COSTS AND OUTCOMES IN HOSPITAL ADMISSIONS FOR TRAUMATIC INJURY IN THE UNITED STATES |
|
Davis KL1, Candrilli SD1, Mitra D1, Tortella BJ2, Joshi AV2 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk Inc, Princeton, NJ, USA |
| |
|
PHP27 |
A NEW REGRESSION MODEL AND QUALITY PERFORMANCE ADJUSTMENT IN PHYSICIAN ECONOMIC PROFILING |
|
Zhao Y1, Robinson M1, Legorreta AP2, Gilmore A1 |
|
1Health Benchmarks, Inc, Woodland Hills, CA, USA, 2UCLA School of Public Health, Woodland Hills, CA, USA |
| |
|
PHP28 |
DEVELOPMENT OF THE CAT-HEALTH SYSTEM: THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS |
|
Rebollo P1, García-Cueto E2, Cuervo J1, Zardain PC1, Martínez I1, Muñiz J2 |
|
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Oviedo University, Oviedo, Spain |
| |
|
PHP29 |
THE RELATIONSHIP BETWEEN PHYSICIAN EMPATHY AND SATISFACTION WITH PRIMARY CARE PHYSICIANS: FINDINGS FROM AN INTERNET BASED SURVEY |
|
Uhas AA1, Feldman SR2, Balkrishnan R1 |
|
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA |
| |
|
PHP30 |
HEALTH OUTCOMES AMONG INDIVIDUALS WITH AND WITHOUT HEALTH INSURANCE IN THE UK: RESULTS OF A MATCHED SAMPLE ANALYSIS OF A RETROSPECTIVE DATABASE |
|
Bolge SC, Kannan H |
|
Consumer Health Sciences, Princeton, NJ, USA |
| |
|
PHP31 |
EUROPEAN PRICING AND REIMBURSEMENT UPDATE: OPTIMAL MONETARY BENEFITS CAN DEPEND ON WHICH COUNTRY THE PROCESS IS INITIATED |
|
Perard R, Gairy K, Gani R |
|
Heron Group, Letchworth Garden City, UK |
| |
|
PHP32 |
OBTAINING VALUE FOR MONEY FROM PHARMACEUTICALS: REFERENCE PRICING OR HEALTH TECHNOLOGY ASSESSMENT? |
|
Drummond M1, Jönsson B2, Rutten F3, Stargardt T4 |
|
1University of York, York, Heslington, UK, 2Centre for Health Economics, Stockholm, Sweden, 3IMTA, Rotterdam, The Netherlands, 4Berlin University of Technology, Berlin, Germany |
| |
|
PHP33 |
RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS |
|
Karia R, Gani R, Boler A |
|
Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK |
| |
|
PHP34 |
EXAMINING INCENTIVES FOR SUBGROUPING IN NICE SUBMISSIONS |
|
Muston D |
|
Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK |
| |
|
PHP35 |
PROFILE OF PHYSICIANS' PRESCRIPTION IN GREECE |
|
Tsiantou V1, Zavras D1, Geitona M2, Kyriopoulos J1 |
|
1National School of Public Health, Athens, Greece, 2University of Thessaly, Volos, Greece |
| |
|
PHP36 |
PATIENT TRANSFER DECREASE AND HEALTH INSURANCE COSTS SAVINGS ASSOCIATED WITH TELEMEDICINE CONSULTATION. EXAMPLE OF THE TELEMEDICINE NETWORK OF “MIDI-PYRéNéES” (RTR) |
|
Billon S1, Lareng L2, Salvodelli M2, Bourguignon S1, Leclercq C2 |
|
1AREMIS Consultants, Neuilly-sur-Seine, France, 2Institut Européen de Télémédecine, Toulouse Cedex 9, France |
| |
|
PHP37 |
PHARMACOECONOMIC EDUCATION IN COLLEGES OF PHARMACY - 2007 |
|
Reddy M, Rascati KL, Wahawisan J |
|
The University of Texas, Austin, TX, USA |
| |
|
PHP38 |
PREVALENCE OF PALLIATIVE CARE NEEDS IN A COMMUNITY-BASED PUBLIC HOSPITAL |
|
Rankin S1, Conner TM2, Schuch S1, Strassels SA3 |
|
1Brackenridge Hospital, Austin, TX, USA, 2Outcomes Research Consulting, Austin, TX, USA, 3University of Texas at Austin College of Pharmacy, Austin, TX, USA |
| |
|
PHP39 |
PROVISION OF ESSENTIAL MEDICINES AND PHYSICIANS QUALITY PERCEPTION OF ARGENTINA HEALTH CARE SERVICES |
|
Maceira DA1, Kremer P2 |
|
1Center for the Study of the State and Society, Buenos Aires, Argentina, 2Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC), Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina |
| |
|
PHP40 |
PHARMACOECONOMIC EVALUATION IN THE IRISH HEALTH CARE SETTING |
| |
Usher C, Tilson L, Ryan M, O'Leary A, Barry M |
| |
National Centre for Pharmacoeconomics, Dublin 8, Ireland |
INDIVIDUAL’S HEALTH
PIH1 |
ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY AND COMORBID MEDICAL ILLNESS: LARGE-SCALE RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID-ENROLLED CHILDREN |
|
Hankin C1, Silverman L2, Wang Z1, Bronstone A1 |
|
1BioMedEcon, Moss Beach, CA, USA, 2Goryeb Children's Hospital, Morristown, NJ, USA |
| |
|
PIH2 |
RISK-ADJUSTED MALNUTRITION STATUS AS PREDICTOR FOR CLINICAL OUTCOMES IN HOSPITALIZED PATIENTS (RAMP) |
|
Fischer FJ, Goeke T, Gohlke A |
|
Schellen und Partner, Düsseldorf, NRW, Germany |
| |
|
PIH3 |
ENDOMETRIOSIS: COST ESTIMATES AND METHODOLOGICAL PERSPECTIVE |
|
Simoens S1, D'Hooghe T2 |
|
1Katholieke Universiteit Leuven, Leuven, Belgium, 2University Hospitals Leuven, Leuven, Belgium |
| |
|
PIH4 |
DRUG COSTS AT THE END OF LIFE |
|
Reymen J1, Willems L2, Simoens S1 |
|
1Katholieke Universiteit Leuven, Leuven, Belgium, 2University Hospitals Leuven, Leuven, Belgium |
| |
|
PIH5 |
COSTS AND OUTCOMES ASSOCIATED WITH USE OF RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH) DURING IN VITRO FERTILISATION (IVF) TREATMENT IN A UK CENTRE |
|
Ledger WL1, Wiebinga CJ2, Holman AJ3, Irwin DE4, Lloyd AC3 |
|
1University of Sheffield, Sheffield, UK, 2N.V. Organon, Oss, The Netherlands, 3Fourth Hurdle Consulting, London, UK, 4University of North Carolina, Chapel Hill, NC, USA |
| |
|
PIH6 |
INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY AMONG PEDIATRICS IN THE UNITED STATES |
|
Mitra D1, Candrilli SD1, Davis KL1, Tortella BJ2, Joshi AV2 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk, Inc, Princeton, NJ, USA |
| |
|
PIH7 |
COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS |
|
O'Sullivan AK1, Weinstein MC2, Thompson D1, Chu P1, Lee DW3, Stewart EA4 |
|
1i3 Innovus, Medford, MA, USA, 2Harvard University, Boston, MA, USA, 3GE Healthcare, Waukesha, WI, USA, 4Mayo Clinic, Rochester, MN, USA |
| |
|
PIH8 |
COST EFFECTIVENESS MODELLING OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS II, AN ULTRA-ORPHAN DISEASE |
|
Thompson G1, Cox P2, Clayton J2 |
|
1Bridgehead International Ltd, Melton Mowbray, Leicestershire, UK, 2Shire Human Genetic Therapies UK Ltd, Basingstoke, UK |
| |
|
PIH9 |
ESTIMATION OF HEALTHCARE PROFESSIONALS' TIME INPUT USING MULTI-DIMENSIONAL WORK SAMPLING (MDWS) |
|
Patterson SM1, Crealey GE2, Hughes CM1 |
|
1Queen's University Belfast, Belfast, Co. Antrim, UK, 2Clinical Research Support Centre, Belfast, Northern Ireland, UK |
| |
|
PIH10 |
AN ECONOMIC ASSESSMENT OF THE CONTENT OF HOME PHARMACIES AND SELF MEDICATION PRACTICE AMONG FAMILIES IN SLOVAK REPUBLIC AND SERBIA CITIES. |
|
Sabo A1, Tomic Z2, Šramka M3, Juris P3 |
|
1Faculty of Medicine, Novi Sad, Serbia and Montenegro, 2Medical School of the University in Novi Sad, Novi Sad, Serbia and Montenegro, 3High School of Saint Elisabeth, Bratislava, Slovak Republic |
| |
|
PIH11 |
ROLE OF BLACK BOX WARNINGS AND FORMULARY MANAGEMENT |
|
Cohen JP1, Young B2 |
|
1Erasmus University, Rotterdam, The Netherlands, 2Tufts University, Boston, MA, USA |
| |
|
PIH12 |
HORMONE REPLACEMENT THERAPY OF MENOPAUSAL WOMEN – ANALYSIS OF PRESCRIPTION PATTERN CHANGES BEFORE AND AFTER THE WHI STUDY USING CLAIMS DATA OF A GERMAN SICKNESS FUND |
|
Gothe H1, Seidlitz C1, Höer A1, Glaeske G2, Häussler B1 |
|
1IGES Institute for Healthcare and Social Research, Berlin, Germany, 2ZeS, Centre of Social Policy Research, Faculty 11: Human and Health Sciences, University of Bremen, Bremen, Germany |
| |
|
PIH13 |
FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER |
|
Zammit DC1, Hay JW1, Globe DR2, Sugar CA3, Gauderman WJ1 |
|
1University of Southern California, Los Angeles, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3UCLA, Los Angeles, CA, USA |
| |
|
PIH14 |
DESCRIBING YOUR HEALTH TODAY: ANALYSIS OF OPEN ANSWERS IN THE VALIDATION PROCEDURE OF THE ITALIAN EQ-5D(CHILD) VERSION |
|
Tomasetto C1, Matteucci MC1, Selleri P1, Cavrini G1, Pacelli B2, Broccoli S1, Scalone L3 |
|
1University of Bologna, Bologna, Italy, 2Health Authority of Bologna, Bologna, Italy, 3Centre of Pharmacoeconomics, Milan, Italy |
| |
|
PIH15 |
ADJUSTING FOR TRIAL QUALITY IN A META-ANALYSIS |
|
Zammit DC1, Hay JW1, Globe DR2, Sugar CA3, Gauderman WJ1 |
|
1University of Southern California, Los Angeles, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3UCLA, Los Angeles, CA, USA |
| |
|
PIH16 |
INTERNET SURVEY: A NEW AND VALID TOOL TO ESTIMATE THE BURDEN OF OTITIS IN CHILDREN <5 YEARS OLD |
|
Stolk EA1, Mangen MJ2, Wolleswinkel-van den Bosch J3, Laplante S4 |
|
1Erasmus Medical Center, Rotterdam, The Netherlands, 2National Institute of Public Health and the, Bilthoven, The Netherlands, 3Pallas Health Research and Consultancy B.V, Rotterdam, The Netherlands, 4GlaxoSmithKline Biologicals, Rixensart, Belgium |
| |
|
PIH17 |
WITHDRAWN |
| |
|
PIH18 |
VALIDITY OF A CHILD-FRIENDLY EQ-5D AS A GENERIC HEALTH OUTCOME INSTRUMENT IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS IN GERMANY |
|
Eidt D1, Greiner W2, Mittendorf T1, Von der Schulenburg JM1 |
|
1Leibniz University of Hannover, Hannover, Germany, 2University of Bielefeld, Bielefeld, Germany |
| |
|
PIH19 |
TEMPORAL PATTERNS IN HEALTH RELATED QUALITY OF LIFE IN HOSPITALIZED PATIENTS IN THE UK |
|
Wechowski JG, Spiewanowski P, McEwan P |
|
Cardiff Research Consortium, Cardiff, Wales, UK |
| |
|
PIH20 |
ASSOCIATION BETWEEN METABOLIC SYNDROME AND QUALITY OF LIFE IN MALE STAINLESS STEEL WORKERS |
|
Yen JMC1, Wang JD2, Yen CH3, Du CL4 |
|
1E-DA Hospital/I-SHOU University, Yan-Chau Shiang, Kaohsiung County, Taiwan, 2National Taiwan University, College of Public Health, Taipei, Taiwan, 3Kaohsiung Medical University, School of Dentistry, Kaohsiung, Taiwan, 4National Taiwan University Hospital, Taipei, Taiwan |
| |
|
PIH21 |
CORRELATES OF PATIENT SATISFACTION WITH PHYSICIAN VISIT: DIFFERENCES BETWEEN ELDERLY AND NON-ELDERLY SURVEY RESPONDENTS |
|
Kong MC1, Feldman SR2, Balkrishnan R1 |
|
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA |
| |
|
PIH22 |
WILLINGNESS TO PAY OF YOUNG GREEK WOMEN FOR THE NEW ANTI-HUMAN PAPILOMA VIRUS VACCINE |
|
Kalampokas T1, Maravelakis PE2, Gregory S1, Athanasakis K1, Geitona M3, Kyriopoulos J1 |
|
1National School of Public Health, Athens, Greece, 2University of Aegean, Karlovasi Samou, Greece, 3University of Thessaly, Volos, Greece |
|
|
NEUROLOGICAL DISORDERS
PND1 |
BUDGETARY ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA) |
|
Navarro Espigares JL1, Maestre Moreno J2, Hernández Torres E3, Gonzalez Lopez JM1 |
|
1University Hospital Virgen de las Nieves, Granada, Spain, 2University Hospital Virgen de las Nieves, Granada, AZ, Spain, 3University of Granada, Granada, Spain |
| |
|
PND2 |
BUDGET IMPACT ANALYSIS OF LEVETIRACETAM ADJUNCTIVE THERAPY IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY IN SCOTLAND |
|
Ryan J1, Germe M2, Brown M3 |
|
1Abacus International, Bicester, UK, 2UCB, Braine-l'Alleud, Belgium, 3UCB, Slough, UK |
| |
|
PND3 |
BUDGET IMPACT OF DOPAMINE AGONISTS IN POLAND |
|
Kawalec P1, Czech M2, Faluta T3 |
|
1Centrum HTA, Kraków, Poland, 2Servier Polska, Warszawa, woj. mazowieckie, Poland, 3Servier Polska, Warsaw, Poland |
| |
|
PND4 |
DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH TREATMENTS OF NEUROLOGICAL DISORDERS |
|
Tesar T1, Foltan V1, Tomek D2, Ilavska A3 |
|
1Comenius University, Bratislava, Slovak Republic, 2Health Insurance Fund Apollo, Bratislava, Slovak Republic, 3Railway Hospital, Bratislava, Slovak Republic |
| |
|
PND5 |
USE OF HEALTH CARE RESOURCES AND CORRESPONDING COSTS IN NEUROLOGICAL DISORDERS IN THE PRIMARY CARE SETTING |
|
Sicras-Mainar A1, Velasco-Velasco S1, Rejas-Gutiérrez J2, Navarro-Artieda R3, Frías-Garrido X4 |
|
1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 4Hospital German Trias y Pujol, Badalona, Barcelona, Spain |
| |
|
PND6 |
COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE |
|
Graham JB1, Earnshaw SR1, Castelli-Haley J2, Oleen-Burkey M2, Johnson KP3 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Teva Neuroscience, Inc, Kansas City, MO, USA, 3University of Maryland, Baltimore, MD, USA |
| |
|
PND7 |
AN ANALYTICAL MODEL TO PREDICT THE COST-EFFECTIVENESS OF LONG-TERM ESZOPICLONE FOR THE TREATMENT OF PRIMARY INSOMNIA |
|
Snedecor SJ1, Botteman MF1, Schaefer K2, Barry N2, Rubens R2, Pickard AS3 |
|
1Pharmerit North America, LLC, Bethesda, MD, USA, 2Sepracor Inc, Marlborough, MA, USA, 3College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA |
| |
|
PND8 |
COST-EFFECTIVENESS ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA) VERSUS THE STANDARD PROTOCOL BASED ON HOSPITALISATION |
|
Navarro Espigares JL1, Maestre Moreno J2, Hernández Torres E3, Gonzalez Lopez JM1 |
|
1University Hospital Virgen de las Nieves, Granada, Spain, 2University Hospital Virgen de las Nieves, Granada, AZ, Spain, 3University of Granada, Granada, Spain |
| |
|
PND9 |
LEVETIRACETAM ADJUNCTIVE THERAPY FOR THE TREATMENT OF REFRACTORY PRIMARY GENERALISED TONIC-CLONIC SEIZURES: A COST-EFFECTIVENESS ANALYSIS |
|
Ryan J1, Germe M2, Brown M3 |
|
1Abacus International, Bicester, UK, 2UCB, Braine-l'Alleud, Belgium, 3UCB, Slough, UK |
| |
|
PND10 |
COST EFFECTIVENESS ANALYSES OF RUFINAMIDE VS TOPIRAMATE AND LAMOTRIGINE AS ADJUNCTIVE THERAPIES IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME (LGS) IN THE UK
|
| |
Benedict Á1, Dale PL2, MacLaine G3, Verdian L3
|
| |
1United BioSource Corporation, Budapest, Hungary, 2United BioSource Corporation, London, UK, 3Eisai Europe Limited, Hatfield, Herthfordshire, UK
|
| |
|
PND11 |
COMPARATIVE ANALYSIS OF MULTIPLE SCLEROSIS COST-EFFECTIVENESS MODELS: FOCUS ON THE UNITED STATES MANAGED CARE PERSPECTIVE |
|
Papshev D1, Bennett R2, AL-Sabbagh A2 |
|
1RXWORX, Inc, Yardley, PA, USA, 2EMD Serono, Inc, Rockland, MA, USA |
| |
|
PND12 |
MODELING THE CLINICAL AND ECONOMIC CONSEQUENCES OF TREATING RELAPSING FORM OF MULTIPLE SCLEROSIS WITH SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON-BETA-1A |
|
Guo S1, Copur D1, Ward A1, O'Brien JA1, Ishak KJ2, Bennett R3, Al-Sabbah A3, Meletiche DM3, Caro JJ1 |
|
1Caro Research Institute, Concord, MA, USA, 2Caro Research Institute, Montreal, QC, Canada, 3EMD Serono, Inc, Rockland, MA, USA |
| |
|
PND13 |
COST-EFFECTIVENESS ANALYSIS OF THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY |
|
Liedgens H1, Hertel N2, Gabriel A2, Nuijten MJC3, Dakin HA4, Spöhrer U5, Poulsen Nautrup B1 |
|
1Grünenthal GmbH, Aachen, Germany, 2IMS Health, Nuremberg, Germany, 3Erasmus University, Rotterdam, The Netherlands, 4Abacus International, Bicester, Oxfordshire, UK, 5University Hospital of Munich, Munich, Germany |
| |
|
PND14 |
COST-EFFECTIVENESS OF PREGABALIN ADD-ON MEDICATION IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN FINLAND |
|
Linden K, Kotomäki T, Sintonen S, Jormanainen V |
|
Pfizer Oy, Helsinki, Finland |
| |
|
PND15 |
THE COST-UTILITY OF EXELON PATCH IN THE MANAGEMENT OF PATIENTS WITH MODERATE ALZHEIMER'S DISEASE IN THE UK |
|
Brennan A1, Nagy B1, Brandtmuller A1, Thomas SK2, Sullivan SD3, Akehurst R1 |
|
1Sheffield University, Sheffield, UK, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3University of Washington, Seattle, WA, USA |
| |
|
PND16 |
OBJECTIVE COSTS AND PREVALENCE OF COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT INSOMNIA |
|
Doan J1, Brook RA2, Kleinman N3, Melkonian AK3, Smeeding J4, Baran RW5 |
|
1Takeda Global Research and Development Center, Deerfield, IL, USA, 2The JeSTARx Group, Newfoundland, NJ, USA, 3The HCMS Group, Cheyenne, WY, USA, 4The JeSTARx Group, Dallas, TX, USA, 5Takeda Global Research and Development Center, Inc, Deerfield, IL, USA |
| |
|
PND17 |
TREATMENT COSTS ASSOCIATED WITH RESTLESS LEGS SYNDROME IN ITALY |
|
Attinà G1, Ferini-Strambi L2, Mennini FS3, Palazzo F4 |
|
1Boehringer- Ingelheim, Milan, Italy, 2Hospital San Raffaele, Vita Salute University of Milan, Milan, Italy, 3Tor Vergata University, Rome, Italy, 4National Research Council, Rome, Italy |
| |
|
PND18 |
HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING UNDER ROUTINE MEDICAL PRACTICE REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA IN PRIMARY CARE SETTING (PCS): A 12-WEEKS LONGITUDINAL POST-HOC ANALYSIS |
|
Navarro A1, Pérez C2, Saldaña MT3, Torrades S4, Rejas J5 |
|
1Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 2Hospital University La Princesa, Madrid, Spain, 3Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 4European Biometric Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
PND19 |
WITHDRAWN |
|
|
|
|
| |
|
PND20 |
COST-UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY |
|
Liedgens H1, Hertel N2, Gabriel A2, Nuijten MJC3, Dakin HA4, Spöhrer U5, Poulsen Nautrup B1 |
|
1Grünenthal GmbH, Aachen, Germany, 2IMS Health, Nuremberg, Germany, 3Erasmus University, Rotterdam, The Netherlands, 4Abacus International, Bicester, Oxfordshire, UK, 5University Hospital of Munich, Munich, Germany |
| |
|
PND21 |
INSOMNIA AND SLEEP LOSS: WORKPLACE PRODUCTIVITY LOSS AND ASSOCIATED COSTS |
|
Mallis MM1, Rosekind MR1, Lerner D2, Seal B3, Brandt SL1, Gregory KB1 |
|
1Alertness Solutions, Cupertino, CA, USA, 2Tufts-New England Medical Center, Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA |
| |
|
PND22 |
MILD TO MODERATE ALZHEIMER'S DISEASE ASSOCIATED WITH SIGNIFICANT TIME BURDEN TO CAREGIVERS |
|
Jonsson L1, Grundman M2, Black R3, Liu E2, Minassian S2, Zbrozek A4, Leibman C5, Lucas C6, McLaughlin T7 |
|
1i3 Innovus, Stockholm, Sweden, 2Elan Pharmaceuticals, San Diego, CA, USA, 3Wyeth Research, Collegeville, PA, USA, 4Wyeth Research, Philadelphia, PA, USA, 5Elan Pharmaceuticals, Inc, San Diego, CA, USA, 6Elan Pharmaceuticals, Stevenage, UK, 7Elan Pharmaceuticals, South San Francisco, CA, USA |
| |
|
PND23 |
A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-1A |
|
Castelli-Haley J1, Oleen-Burkey M1, Lage MJ2 |
|
1Teva Neuroscience, Inc, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, LLC, Groton, CT, USA |
| |
|
PND24 |
TRENDS IN ANTI-ALZHEIMER'S MEDICATION UTILIZATION AND ASSOCIATED PATIENT CHARACTERISTICS IN SPAIN: RESULTS FROM A LARGE MULTI-CENTER ALZHEIMERMONITOR INITIATIVE |
|
Narayanan S1, Pedrosa RG2 |
|
1TNS Healthcare, Stamford, CT, USA, 2TNS Healthcare, Madrid, Spain |
| |
|
PND25 |
TREATMENT PATTERNS AND PATIENT CHARACTERISTICS IN PARKINSON'S DISEASE (PD): RESULTS FROM A LARGE MULTI-CENTER NEUROMONITOR INITIATIVE IN SPAIN |
|
Narayanan S1, Pedrosa RG2 |
|
1TNS Healthcare, Stamford, CT, USA, 2TNS Healthcare, Madrid, Madrid, Spain |
| |
|
PND26 |
USE OF A COUNSELLING GUIDELINE FOR THE DETECTION OF DRUG RELATED PROBLEMS IN PARKINSON'S DISEASE |
|
Schroeder S1, Schaefer M2 |
|
1Charité University Medicine Berlin, Berlin, Germany, 2Institut für Klinische Pharmakologie, Berlin, Germany |
| |
|
PND27 |
ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS |
|
Brown MG1, Skedgel C1, Hicks VA2, Sketris IS2, Fisk JD1 |
|
1Capital Health Nova Scotia, Halifax, NS, Canada, 2Dalhousie University, Halifax, NS, Canada |
| |
|
PND28 |
COMPARISON OF FOUR PREFERENCE-BASED SF-36/SF-12 ALGORITHMS TO EVALUATE THE COST-EFFECTIVENESS OF TREATMENT FOR PRIMARY INSOMNIA WITH ESZOPICLONE |
|
Snedecor SJ1, Botteman MF1, Schaefer K2, Barry N2, Rubens R2, Pickard AS3 |
|
1Pharmerit North America, LLC, Bethesda, MD, USA, 2Sepracor Inc, Marlborough, MA, USA, 3College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA |
| |
|
PND29 |
RETROSPECTIVE MEASUREMENT OF UNCODED DISEASE OUTCOMES IN A CLAIMS DATABASE |
|
Krukas MR, Berenson K, Hendlish S, Doyle J |
|
Analytica International, New York, NY, USA |
| |
|
PND30 |
ANALYSIS OF TRIPTAN REFILLING BEHAVIOR AMONG FEMALE MIGRAINEURS |
|
Puenpatom RA, Victor TW |
|
Endo Pharmaceuticals, Chadds Ford, PA, USA |
| |
|
PND31 |
DEVELOPMENT OF THE ALZHEIMER'S DISEASE CAREGIVER PREFERENCE QUESTIONNAIRE |
|
Abetz L1, Mertzanis P2, Rofail D1, Tellefsen C2, Thompson G1, McBurney CR3, Thomas SK4 |
|
1Mapi Values, Bollington, Cheshire, UK, 2Mapi Values, Boston, MA, USA, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corp, East Hanover, NJ, USA |
| |
|
PND32 |
ALZHEIMER'S DISEASE PROGRESSION HEALTHY-YEAR EQUIVALENTS: STATED RISK-BENEFIT TRADE-OFF PREFERENCES |
|
Johnson FR1, Hauber AB1, Mohamed AF1, Leibman C2, Arrighi HM2 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Elan Pharmaceuticals, Inc, San Diego, CA, USA |
| |
|
PND33 |
THE RELATIONSHIP BETWEEN THE MEDICATION POSSESSION RATIO AND PATIENT OUTCOMES: EVIDENCE FROM THE USE OF GLATIRAMER ACETATE |
|
Castelli-Haley J1, Oleen-Burkey M1, Lage MJ2 |
|
1Teva Neuroscience, Inc, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, LLC, Groton, CT, USA |
| |
|
PND34 |
A QUALITATIVE STUDY OF THE INDIVIDUALISED IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE |
|
Speight J, Reaney M, Showumni O |
|
AHP Research Ltd, Uxbridge, Middlesex, UK |
| |
|
PND35 |
MEASURING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE: A SYSTEMATIC REVIEW |
|
Speight J, Reaney M, Showumni O |
|
AHP Research Ltd, Uxbridge, Middlesex, UK |
| |
|
PND36 |
FIT OF THE MIGRAINE PREVENTION ASSESSMENT CLINICAL TOOL (M-PACT) WITH QUALITATIVE DEVELOPMENT GUIDELINES FOR PATIENT REPORTED OUTCOMES |
|
Cole JC1, Lin P1, Kite A1, Caleo S2 |
|
1QualityMetric, Lincoln, RI, USA, 2Johnson & Johnson Pharmaceuticals, Belguim, Beerse, Belgium |
| |
|
PND37 |
A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS |
|
Hoffman DL1, Mychaskiw MA2 |
|
1Deborah Hoffman, PhD, LLC, New Haven, CT, USA, 2Pfizer, Inc, New York, NY, USA |
| |
|
PND38 |
LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA: A POST-HOC ANALYSIS OF A 12-WEEK PROSPECTIVE STUDY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE |
|
Saldaña MT1, Pérez C2, Navarro A3, Martínez S4, Rejas J5 |
|
1Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 2Hospital University La Princesa, Madrid, Spain, 3Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
PND39 |
PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PARKINSON'S DISEASE: OVERVIEW OF US AND EUROPEAN DRUG APPROVALS |
|
Caron M1, Emery MP1, Marquis P2, Piault E2 |
|
1Mapi Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA |
| |
|
PND40 |
WITHDRAWN |
| |
|
PND41 |
EFFECTIVENESS OF PRAMIPEXOLE IN THE TREATMENT OF RLS AND THE EFFECT ON WORK PRODUCTIVITY: A 12-WEEKS NON-INTERVENTIONAL TRIAL IN PATIENTS WITH PRIMARY RESTLESS LEGS SYNDROM (RLS) |
|
Eisensehr I1, Möller C2, Köster J2, Brüggenjürgen B3 |
|
1Neurologie in der Sendlinger Straße, München, Germany, 2Boehringer-Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany, 3Charité University Medical Center, Berlin, Germany |
|
|
OSTEOPOROSIS
POS1 |
EFFICACY OF ZOLEDRONIC ACID RELATIVE TO OTHER TREATMENTS FOR VERTEBRAL FRACTURES IN OSTEOPOROSIS: RESULTS OF A BAYESIAN MIXED TREATMENT COMPARISON |
|
Bergman G1, Olson M2, Huels J2, Jansen JP1 |
|
1Mapi Values, Houten, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland |
| |
|
POS2 |
CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES |
|
Sebestyén A1, Tóth F2, Sándor J2, Gulácsi L3, Brodszky V3, Nyárády J2, Boncz I2 |
|
1National Health Insurance Fund Administration, Pécs, Hungary, 2University of Pécs, Pécs, Hungary, 3Corvinus University of Budapest, Budapest, Hungary |
| |
|
POS3 |
THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE |
|
Sebestyén A1, Sándor J2, Nyárády J2, Betlehem J2, Gulácsi L3, Péntek M4, Boncz I2 |
|
1National Health Insurance Fund Administration, Pécs, Hungary, 2University of Pécs, Pécs, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4Flor Ferenc County Hospital, Kistarcsa, Hungary |
| |
|
POS4 |
ECONOMIC IMPACT OF FRENCH NEW GUIDELINES ON POST-MENOPAUSAL OSTEOPOROSIS DIAGNOSIS |
|
Cotte FE1, Fardellone P2, Roux C3, Lespessailles E4, Gaudin AF1 |
|
1GlaxoSmithKline France, Marly le Roi, France, 2CHU Nord Hospital, Amiens, France, 3Cochin Hospital, Paris, France, 4CHR Orleans, Orleans, France |
| |
|
POS5 |
LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS |
|
Cowell W1, Palmer K1, Hughes D2 |
|
1Roche, Welwyn Garden City, UK, 2University of Wales, Bangor, Bangor, UK |
| |
|
POS6 |
COST-EFFECTIVENESS OF OSTEOPOROSIS SCREENING CAMPAIGN FOR BELGIAN WOMEN |
|
Hiligsmann M, Bruyère O, Ethgen O, Reginster JY |
|
University of Liège, Liège, Belgium |
| |
|
POS7 |
COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS. |
|
Fardellone P1, Cortet B2, Thomas T3, Legrand E4, Bresse X5, Bisot-Locard S5, Beresniak A6 |
|
1CHU Amiens, Amiens, France, 2CHRU Lille, Lille, France, 3INSERM E0366, Saint-Etienne, France, 4CHU, Angers, France, 5Novartis pharma, rueil malmaison, France, 6Data Mining International, Geneva, Switzerland |
| |
|
POS8 |
COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID 5 MG FOR THE MANAGEMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN THE UK SETTING |
|
Olson M1, Brereton N2, Huels J1, Roberts D3, Akehurst R2 |
|
1Novartis Pharma AG, Basel, Switzerland, 2University of Sheffield, Sheffield, UK, 3Novartis Pharmaceuticals UK Ltd, Frimley, UK |
| |
|
POS9 |
COMPARATIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TERIPARATIDE [RHPTH(1-34)] VERSUS RHPTH(1-84) |
|
Borgström F1, Ström O2, Kutahov A3, Marin F3, Ljunggren Ö4 |
|
1European Health Economics, Stockholm, Sweden, 2Stockholm Health Economics, Stockholm, Uppland, Sweden, 3Eli Lilly Research Centre Ltd, Windlesham, UK, 4Uppsala University Hospital, Uppsala, Sweden |
| |
|
POS10 |
COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG KOREAN ELDERLY WOMEN: INCIDENCE-BASED APPROACH |
|
Kang HY1, Park S2, Kang DR3, Kim JY4, Chang YH5, Choi WJ2, Moon SH6, Yang KH6, Park JY7, Kwon SY8 |
|
1Yonsei University, Seoul, South Korea, South Korea, 2Health Insurance Review Agency, Seoul, South Korea, 3Severance Hospital Clinical Trials Center, Seoul, South Korea, 4Yonsei University, Seoul, South Korea, 5Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea, 6Department of Orthopedics, College of Medicine, Yonsei University, Seoul, South Korea, 7Konkuk University, Seoul, South Korea, 8The Catholic University of Korea, Seoul, South Korea |
| |
|
POS11 |
FALL-RELATED HOSPITALIZATION AND FACILITY COSTS AMONG RESIDENTS RECEIVING LONG-TERM CARE |
|
Carroll NV1, Delafuente JC1, Cox FM2, Narayanan S3 |
|
1Virginia Commonwealth University, Richmond, VA, USA, 2Pfizer, Inc, New York, NY, USA, 3Beverly Enterprises, Fort Smith, AR, USA |
| |
|
POS12 |
USE OF OSTEOPOROSIS MEDICATIONS FOLLOWING A FRACTURE |
|
Herman EO, Carroll NV |
|
Virginia Commonwealth University, Richmond, VA, USA |
| |
|
POS13 |
IMPACT OF THE ALLOWABLE GAP ON PERSISTENCE IN THE BISPHOSPHONATE MARKET |
|
Henderson SC1, Von Allmen H1, Weiss TW2 |
|
1IMS Health, Blue Bell, PA, USA, 2Merck & Co., Inc, West Point, PA, USA |
| |
|
POS14 |
COMPARISON OF SF-6D AND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS |
|
Golicki D1, Latek MM2 |
|
1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2George Mason University, Fairfax, VA, USA |
|
|
10th Annual European Congress Main Page
|
|